Australia - Inggris - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.78 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.806 mg) - drug delivery system, transdermal - excipient ingredients: povidone; dipropylene glycol; oleyl alcohol; ethyl acetate; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; simethicone; dimeticone; xylene; cyclomethicone - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.78 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.806 mg) - drug delivery system, transdermal - excipient ingredients: povidone; dipropylene glycol; oleyl alcohol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Uni Eropa - Inggris - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoma - pituitary and hypothalamic hormones and analogues - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Singapura - Inggris - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - (blue tablet) estradiol hemihydrate 2.07mg equivalent to; (red tablet) estradiol hemihydrate 1.03mg equivalent to; (white tablet) estradiol as hemihydrate 2.07mg equivalent to; (white tablet) norethisterone acetate - tablet, film coated - 2 mg - (blue tablet) estradiol hemihydrate 2.07mg equivalent to 2 mg; (red tablet) estradiol hemihydrate 1.03mg equivalent to 1 mg; (white tablet) estradiol as hemihydrate 2.07mg equivalent to 2 mg; (white tablet) norethisterone acetate 1 mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - estradiol hemihydrate (unii: cxy7b3q98z) (estradiol - unii:4ti98z838e) - estradiol 10 ug - yuvafem should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known anaphylactic reaction or angioedema to  yuvafem - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy yuvafem should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. yuvafem should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast m

Amerika Serikat - Inggris - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 10 ug - estradiol vaginal inserts is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.3)]. - breast cancer or a history of breast cancer [see warnings and precautions (5.3)]. - estrogen-dependent neoplasia [see warnings and precautions (5.3)]. - active dvt, pe, or history of these conditions [see warnings and precautions (5.2)]. - active arterial thromboembolic disease (for example, stroke or mi), or a history of these conditions [see warnings and precautions (5.2)]. - known anaphylactic reaction, or angioedema, or hypersensitivity to estradiol vaginal inserts [see warnings and precautions (5.16)]. - hepatic impairment or disease. - protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders. risk summary estradiol vaginal inserts are not indicated for use in pregnancy. there are no data with the use of estradiol vaginal inserts in pregnant women; however, epidemiologic studies and meta-analyses have

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - estradiol hemihydrate estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - estradiol hemihydrate estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day